ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Christina Choy, Kefah Mokbel
Abstract: Ductal carcinoma in-situ DCIS is a heterogeneous entity in breast neoplasm with unpredictable biological behavior. This poses challenge in the management of DCIS. Various trials on DCIS have shown good outcome with integral treatment of adequate sur…
Ahmed Ashour, Gamal El-Husseiny, Amr Abdel Aziz, Waleed O. Arafat
Background: Chemotherapy-induced neutropenia is a major dose-limiting toxicity of systemic cancer chemotherapy, and it is associated with substantial morbidity, mortality, and costs. The ability to predict the group of patients who are at high risk for neutro…
Laura Johnson, Natalie Lichter, Mamie Hextall, Patricia L. Watkins, Tarek A. Dufan, John M. Watkins
Background: Several Phase III randomized trials have demonstrated improved local control and survival for post-mastectomy radiotherapy in patients with high-risk pathologic features. Close or involved surgical margins were not included as high-risk in these p…
Alessandro D’Elia, Vincenza Maiola, Mirena Manucci, Angelo Pichierri, Alessandro Frati, Felice Giangaspero, Maurizio Salvati
Background : Despite advances in surgical and first-line adjuvant treatment, glioblastoma multiforme (GBM) always recurs as disease natural history. Currently, there is no consensus as to the optimal second-line treatment of recurrent GBM. Patients and Method…
Tetsu Yamamoto, Kuniyuki Katano, Shinichi Sugimoto, Akiyoshi Kanazawa, Eiji Hira, Hiroshi Takeda, Yoshitoshi Sato, Yutaka Yamashiro, Yoshitsugu Tajima, Masahide Ikeguchi
Background : This study evaluated the tolerability and efficacy of intermittent oxaliplatin treatment based on mFOLFOX6 using oral uracil-tegafur(UFT) and leucovorin(LV) maintenance therapy in the treatment of elderly patients with advanced colorectal cancer.…
Yoshio Mizuno, Hiromi Fuchikami, Tsuneo Natori, Naoko Takeda, Yuko Inoue, Junichi Yamada, Hiroaki Abe, Hiroshi Seto, Kazuhiko Sato
Purpose: To standardize the methods to measure Ki-67, there is an interest in automating the assessment of Ki-67. Therefore, we reviewed the possibility of introducing an automated analyzer to standardize the Ki-67 evaluation method. Methods: We retrospective…
Yingxuan Tian, Min Yu, Li Sun, Xiaoping Ren, Weifeng Liang, Wenli Shang, Shufen Huo, Linghua Liu, Yajuan Ren, Hongxia Wen, Zhuo Yang, Shenghong Wei, Cairong Wang
To evaluate the diagnosis model of serum tumor biomarker and several clinical features diagnose and classification for lung cancer , the solid protein chip technology (C-12) was used to detect the biomarkers of SF, CEA, CA242, NSE, CA125, CA19-9 and CA15-3 in…
Fatih M. Uckun, Sanjive Qazi
The identification of SYK as a master regulator of apoptosis controlling the activation of the PI3-K/AKT, NF κ B, and STAT3 pathways—three major anti-apoptotic signaling pathways in B-lineage leukemia/lymphoma cells—prompts the hypothesis that rationally desi…
Gouji Toyokawa, Mitsuhiro Takenoyama, Yukito Ichinose
Despite the aggressive pursuit of diagnostic and treatment modalities for lung cancer, the treatment outcomes are still not satisfactory, and even patients with surgically resectable non-small cell lung cancer (NSCLC) are often at considerable risk of sufferi…
Kirsten H. Walen
The present study presents cytogenetics/cytology of haploidization in the origin of a new, fast growing diploid, small cell-type (F-dPCs). The sequence of events was haploid groupings of the chromosomes in normal, human metaphase cells, followed by genomic do…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).